• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Riluzole/Tiglutik

Background

The tablet form of Riluzole, Rilutek, was approved by the Food and Drug Administration (FDA) in USA in 1995 and by the European Medicine Agency (EMA) in Europe in 1996. Tiglutik or Teglutik is an oral suspension formulation of Riluzole for people living with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) that have difficulty swallowing tablets. Riluzole is currently approved in many countries including USA, Canada, Europe, Israel, Australia, Brazil, Japan and China. Furthermore, a thin film version of riluzole is available in the US (with the commercial name of Exservan), in UK and in the EU.

Approved in:  Commercial Name:
USA Riluzole / Rilutek® tablet
Tiglutik® oral suspension
Exservan® orodispersible film
Europe/EU Riluzole / Rilutek® tablet
Teglutik® oral suspension
Emylif® orodispersible film
Canada Riluzole / Rilutek® tablet
Tiglutik® oral suspension
Israel Riluzole / Rilutek® tablet
Teglutik® oral suspension
Australia Riluzole / Rilutek® tablet
Teglutik® oral suspension
Brazil Riluzole tablet
Japan Riluzole / Rilutek® tablet
China Riluzole tablet
UK Riluzole / Rilutek® tablet
Teglutik® oral suspension
Emylif® orodispersible film

Proposed Mechanism of Action

Riluzole’s mechanism of action is not fully understood, however, it is thought to interfere with the excessive neurotransmitter (glutamate) release that leads to excitotoxicity in ALS/MND causing a dysregulated neuronal activation. This may lead to neuronal damage and eventually death (Van den Bosch, 2006). Of note, other clinical trials in people living with ALS/MND with compounds that have a similar mechanism of action have failed. Therefore, Riluzole’s action has been hypothesized to expand to other aspects of neurotransmission or even other molecular mechanisms linked to ALS. These hypotheses are currently under investigation.

Clinical Trials

Riluzole was approved based on two international clinical trials that included a total of 1114 people living with ALS/MND (PALS).

In the first study, published in 1994, 155 PALS were treated with 100mg of Riluzole or placebo daily for 12 months. By the end of the study, the treatment extended survival or time until tracheostomy (where a breathing tube is inserted directly into the throat) by roughly three months compared to placebo.

In the second study, published in 1996, 959 PALS were treated with three different concentrations of Riluzole (50, 100, 200mg) or placebo daily for 18 months. Both the 100 and 200mg treated groups showed significant delay in the need for tracheostomy or extended survival when compared to placebo. However, the 200mg dose resulted in more side effects.

Dose and Administration

Riluzole has several brand names, and it comes in three forms:

  • Rilutek tablets contain 50mg of active compound (Riluzole). The recommended dose is 50mg twice daily (every 12 hours) taken orally.
  • Tiglutik or Teglutik is recommended for patients who have difficulty in swallowing or receive nutrition via feeding tube. The dosage recommendation is the same as Rilutek. The FDA approved Tiglutik, in 2018 whereas Teglutik, has been available in the UK since 2015.
  • Exservan comes in a thin film that dissolves on the tongue. Exservan is applied one to two hours prior to a meal.

Riluzole is recommended for all patients diagnosed with ALS, however due to lack of studies, it is unclear whether it is equally effective after five years from symptom onset.

  •  

Reported Side Effects

Riluzole is safe and generally well tolerated at a dose of 100mg daily for up to seven years. The most common side effects are numbness around the mouth, nausea, dizziness, diarrhea, lack of energy, high blood pressure, decreased lung function and abdominal pain. Additionally, rare cases have reported liver injury. Riluzole should be administered and monitored under the care of a physician.

Current Status

In 2020, a study showed that out 15 peer-reviewed studies in PALS treated with riluzole in real-world settings, eight found that survival was a median of 6 to 19 months longer on riluzole than on placebo. Another real world study undertaken in 2025 on the European-based PRECISION-ALS database showed a 7-month median survival benefit with the greatest benefit seen in fast-progressing patients

Riluzole’s effects and safety continue to be investigated in people living with ALS/MND.

International Alliance of ALS/MND Associations
April 2026


Disclaimer: Consult with your doctor to determine if riluzole/Tiglutik is an option for you. Always disclose your medical history, including any drugs, natural supplements, or herbal medicines you are currently using. Your doctor will determine the right plan for your needs.

The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Approved Drugs

  • Nuedexta
  • Radicava/Edaravone
  • Riluzole/Tiglutik
  • Rozebalamin / Methylcobalamin
  • Tofersen/Qalsody

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Timmy, Belgium

    Timmy, Belgium

  • Monica Soriano, Argentina

    Monica Soriano, Argentina

  • David Bishop, UK

    David Bishop, UK

  • Paul Launer, USA

    Paul Launer, USA

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Jack Buzby, USA

    Jack Buzby, USA

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Angelique van der Lit-van Veldhuizen, Netherlands

    Angelique van der Lit-van Veldhuizen, Netherlands

  • Sally Pauls, USA

    Sally Pauls, USA

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Jean

    Jean
    jean

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Wendy Hendrickson, USA

    Wendy Hendrickson, USA

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Willi Klein, UK

    Willi Klein, UK

  • Andrew Langat, Kenya

    Andrew Langat, Kenya

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • David Hall, USA

    David Hall, USA

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Ian Gale, Australia

    Ian Gale, Australia

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • Ann Nicol, USA

    Ann Nicol, USA

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Lee Millard, England

    Lee Millard, England

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Bayley, Australia

    Bayley, Australia

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Christian Bär, Germany

    Christian Bär, Germany

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login